WallStreetZenWallStreetZen

NYSEMKT: TOVX
Theriva Biologics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TOVX

Based on 1 analyst offering 12 month price targets for Theriva Biologics Inc

Min Forecast
$1.00+376.19%
Avg Forecast
$1.00+376.19%
Max Forecast
$1.00+376.19%

Should I buy or sell TOVX stock?

Based on 1 analyst offering ratings for Theriva Biologics Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TOVX stock forecasts and price targets.

TOVX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-31

1 of 1

Forecast return on equity

Is TOVX forecast to generate an efficient return?

Company
N/A
Industry
87.23%
Market
176.82%

Forecast return on assets

Is TOVX forecast to generate an efficient return on assets?

Company
N/A
Industry
26.37%

TOVX earnings per share forecast

What is TOVX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.21
Avg 2 year Forecast
-$0.21
Avg 3 year Forecast
-$0.28

TOVX revenue forecast

What is TOVX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$306.0k+2%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%

TOVX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TOVX$0.21$1.00+376.19%Strong Buy
LEXX$0.39N/AN/A
CRIS$5.02$43.00+756.57%Buy
CVM$1.16N/AN/A
VTGN$0.24N/AN/A
View Top Biotech Stocks

Theriva Biologics Stock Forecast FAQ

Is Theriva Biologics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: TOVX) stock is to Strong Buy TOVX stock.

Out of 1 analyst, 1 (100%) are recommending TOVX as a Strong Buy, 0 (0%) are recommending TOVX as a Buy, 0 (0%) are recommending TOVX as a Hold, 0 (0%) are recommending TOVX as a Sell, and 0 (0%) are recommending TOVX as a Strong Sell.

If you're new to stock investing, here's how to buy Theriva Biologics stock.

What is TOVX's earnings growth forecast for 2026-2028?

(NYSEMKT: TOVX) Theriva Biologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.94%.

Theriva Biologics's earnings in 2026 is -$22,969,000.On average, 4 Wall Street analysts forecast TOVX's earnings for 2026 to be -$9,830,209, with the lowest TOVX earnings forecast at -$9,894,459, and the highest TOVX earnings forecast at -$9,637,460. On average, 4 Wall Street analysts forecast TOVX's earnings for 2027 to be -$9,830,209, with the lowest TOVX earnings forecast at -$9,894,459, and the highest TOVX earnings forecast at -$9,637,460.

In 2028, TOVX is forecast to generate -$12,872,893 in earnings, with the lowest earnings forecast at -$13,492,444 and the highest earnings forecast at -$12,046,825.

What is TOVX's revenue growth forecast for 2026-2028?

(NYSEMKT: TOVX) Theriva Biologics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.77%.

Theriva Biologics's revenue in 2026 is $300,000.On average, 4 Wall Street analysts forecast TOVX's revenue for 2026 to be $14,043,156, with the lowest TOVX revenue forecast at $13,492,444, and the highest TOVX revenue forecast at $14,456,190. On average, 3 Wall Street analysts forecast TOVX's revenue for 2027 to be $0, with the lowest TOVX revenue forecast at $0, and the highest TOVX revenue forecast at $0.

In 2028, TOVX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is TOVX's forecast return on assets (ROA) for 2026-2029?

(NYSEMKT: TOVX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 26.37%.

What is TOVX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year TOVX price target, the average TOVX price target is $1.00, with the highest TOVX stock price forecast at $1.00 and the lowest TOVX stock price forecast at $1.00.

The Wall Street analyst predicted that Theriva Biologics's share price could reach $1.00 by Mar 31, 2027. The average Theriva Biologics stock price prediction forecasts a potential upside of 376.19% from the current TOVX share price of $0.21.

What is TOVX's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSEMKT: TOVX) Theriva Biologics's current Earnings Per Share (EPS) is -$1.13. On average, analysts forecast that TOVX's EPS will be -$0.21 for 2026, with the lowest EPS forecast at -$0.22, and the highest EPS forecast at -$0.21. On average, analysts forecast that TOVX's EPS will be -$0.21 for 2027, with the lowest EPS forecast at -$0.22, and the highest EPS forecast at -$0.21. In 2028, TOVX's EPS is forecast to hit -$0.28 (min: -$0.29, max: -$0.26).

What is TOVX's forecast return on equity (ROE) for 2026-2029?

(NYSEMKT: TOVX) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.